Biotech Showcase 2015, page-82

Lol what a soon to be forgotten about side show.
On 1103 alone....
10-15 mill upfront
40 mill toward phase 3
With additional registration milestones and royalties , the bare minimum market cap post licensing on this drug alone will be circa 60 million. Throw in 6 million from an early access program for 1102 and then finally it's licensing out and whalla you have a market cap in excess of 100 million.
Lol and I'm sure by that stage the threads will be littered with apologies to Mark Diamond and the Board for all the spineless attacks over the last 6 months.